ZEAL stock: buy or sell?

ZEAL stock price: $44.25 5.11% At close on February 14th, 2020

Updated on:
February 14th, 2020


Zealand Pharma A/S shares touched new all time highs again on February/14, marking to $44.60. Shares closed at $44.25 and boosted 5.11%. On Thursday ZEAL skyrocketed a dazzling 8.55%.

Zealand Pharma A\u002FS, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark.

Should I buy ZEAL stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

These 2 buy setups are elegible for Zealand Pharma A/S stock now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Zealand Pharma A/S stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for ZEAL stock for the last 30 days.

ZEAL stock analysis

Daily outlook

Zealand Pharma A/S shares topped new all time highs back again on February 14th, marking to $44.60. Shares ended at $44.25 and boosted 5.11%.

Zealand Pharma A/S topped new all time highs back again on February 14th, setting highs to $44.60. Shares ended at $44.25 and boosted 5.11%.

ZEAL stock chart (daily)

Weekly outlook

Zealand Pharma A/S ended this week at $44.25 after marking a new all time high ($44.60) and skyrocketed an outstanding 16.48%. Late December 2019 ZEAL plunged a hair-raising -6.38% in just one week.

ZEAL shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom last week, ZEAL climbed unceasignly breaking out to new all time highs. Early April, SMA20w and SMA40w crossed up triggering a rise of 130.83%. Early September ZEAL price bounced up over the SMA of 20 weeks that acted as support stopping new slides.

ZEAL stock chart (weekly)

ZEAL stock price history

ZEAL stock went public on August 9th, 2017 with a price of $18.121. Since then, ZEAL stock grew a 144.20%, with an average of 72.10% per year. If you had invested right after ZEAL's IPO a $1,000 in ZEAL stock in 2017, it would worth $1,442.00 today.

1: Adjusted price after possible price splits or reverse-splits.

ZEAL stock historical price chart

ZEAL stock reached all-time highs on Feb/14 with a price of $44.60.

ZEAL stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ZEAL stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price prediction for Zealand Pharma A/S stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Zealand Pharma A/S failed analysts on March when it published an Earnings per Share (EPS) of $-0.61 when the analysts' forecast was $-0.69.
ZEAL earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Zealand Pharma A/S annual revenues plummed a scary -72.14% to $37.98 M USD from $136.32 marked in 2017. In contrary, its profit margin (compared to revenues) rocketed to 1,530.62%, that is $581.28 million.

ZEAL annual Sales and Income evolution
2013$6.57 M-$-183.68 M-2795.7%-
2014$154 M2,240.53%$-64.99 M-42.3%-64.62%
2015$188 M22.05%$-113.96 M-60.7%75.35%
2016$235 M25.10%$-153.91 M-65.6%35.06%
2017$136 M-41.94%$-275.26 M-201.9%78.84%
2018$38 M-72.14%$581 M1530.6%-311.18%

Quarterly financial results

Zealand Pharma A/S posted $13.12 million in revenues for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-122.97 M with a profit margin of -937.37%. Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Zealand Pharma A/S sales marked an outstanding gain and skyrocketed a 24.67%.
ZEAL quarterly Sales and Income evolution
2017-Q1$78 M-$-26 M-33.9%-
2017-Q2$11 M-86.09%$-94 M-867.4%255.79%
2017-Q3$6 M-41.44%$-7 M-105.5%-92.88%
2017-Q4$11 M66.39%$-111 M-1051.6%1,559.25%
2018-Q1$11 M2.91%$-91 M-844.1%-17.40%
2018-Q2$15 M39.77%$-127 M-840.1%39.12%
2018-Q4$13 M-13.33%$-123 M-937.4%-3.29%

Zealand Pharma A/S ownership

When you are planning to buy shares of a company, it's always worth to have a look its ownership structure.

Zealand Pharma A/S shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.

In case of Zealand Pharma A/S stock, 8.21% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ZEAL stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Zealand Pharma A/S:

Market cap$1.6 B
Total shares36.0 M
Float shares26.8 M
  - Institutional holdings (%)8.2%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

ZEAL summary

Friday, February 14th, 2020
Day range$42.19 - $44.60
Previous close$42.10
Session gain5.11%
Average true range$1.91
50d mov avg$34.81
100d mov avg$31.62
200d mov avg$26.39
Daily pattern
Weekly pattern lb03c

Zealand Pharma A/S performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Zealand Pharma A/S against in the following table:

Zealand Pharma A/S competitors

Unfortunately, we could not find any public company that could be defined as Zealand Pharma A/S competitor. This doesn't mean Zealand Pharma A/S does not have any competitor in the market, it's just we could not detected it.